Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Tesaro (TSRO) to finish Phase 1/2 study of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas in July 2016

Source Link:: https://clinicaltrials.gov/ct2/show/NCT02048488?term=tesaro&rank=10&submit_fld_opt=

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

TSRO

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details TSR-011 is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinases (TRK). Preliminary clinical activity has been observed in this study in one papillary thyroid carcinoma patient and one pancreatic cancer patient without ALK expression, and in three patients with ALK-positive non-small cell lung cancer (NCSLC) who progressed following prior treatment with crizotinib

http://ir.tesarobio....

Additional Relevant Details terminated

http://ir.tesarobio....

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Oct 29, 2015

Occurred Source:

http://ir.tesarobio.com/releasedetail.cfm?ReleaseID=939351

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1/2 Study, Tsr-011, Oral Tsr-011, Solid Tumors, Lymphoma